pharmaphorum

JANUARY 11, 2022

Bristol-Myers Squibb chief executive Giovanni Caforio has promised to invest in the company’s pipeline at the virtual JP Morgan Healthcare Conference, and demonstrated that commitment by licensing up to four cancer cell therapy candidates from Century Therapeutics.

Clinical Trials 97

Clinical Trials Clinical Trials Licensing Licensing 97

The Pharma Data

OCTOBER 20, 2020

MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. With the advancement of our leading programs such as TLC599 into the commercial phase, now is an opportune time to welcome the return of Mr. Bliss to TLC.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Business Development Genome Genomics 52

pharmaphorum

SEPTEMBER 8, 2020

Both deals give Exelixis an exclusive option to license ADC candidates at the preclinical stage, before they are submitted for approval to start human trials, and can be extended if the parties agree. Last year, Exelixis paid $7.5 million in milestones.

Antibody 52

Antibody Licensing Licensing Drugs 52

Camargo

SEPTEMBER 23, 2020

Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

WCG Clinical

APRIL 3, 2023

Individual subscriptions , customized multi-user, and company licenses to FDAnews are also available. Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.

Compliance 52

Compliance Drugs Manufacturing Regulation 52

pharmaphorum

MAY 18, 2022

The US pharma group is paying $47 million in upfront payments to license rights to the undisclosed drug outside China, Hong Kong, Macao, and Taiwan, with another $1.36 billion in potential milestone payments plus royalties on sales. Davis said the company is “not seeing a fundamental shift in seller expectations as of this point.”

Drugs 59

Drugs Antibody Licensing Licensing 59

pharmaphorum

SEPTEMBER 27, 2022

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics. The post Lava fires up a $700m cancer licensing deal with Seagen appeared first on.

Licensing 110

Licensing Licensing FDA Approval Clinical Trials 110

pharmaphorum

SEPTEMBER 28, 2022

For Roche, the new partnership adds to a string of other business development deals aimed at extending its position in cancer cell therapies – a category where it has lagged behind rivals, including Novartis, Gilead Sciences, and Bristol-Myers Squibb.

Gene Editing 59

Gene Editing Genome Genomics Engineer 59

Drug Discovery World

JANUARY 23, 2024

Hardiman, Senior Director, Ventures – Business Development at Astellas, weighed in: “You’ve got to be intentional and creative to raise funds. As an R&D pipeline and business develops in an increasingly multi-disciplinary sector, new competencies are required to progress.

Life Science 59

Life Science Business Development Protein Development 59

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. She joined the Novartis COVID-19 R&D Task Force to help tackle the emerging pandemic, taking the reins of the business development workstream.

Business Development 52

Business Development Licensing Licensing Development 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Photo courtesy of Bayer. While these are three companies considered key to the future of Bayer’s C&GT Platform, the company is not done fleshing out this new area.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Licensing 52

Licensing Licensing Medicine Development 52

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases.

Immune Response 59

Immune Response Antibody Drugs Licensing 59

Drug Discovery World

JANUARY 30, 2024

Natalia Elizalde, Chief Business Development Officer, VIVEbiotech, says that Dr Naldini’s award represents the significant benefits and demonstrated safety of the therapies developed using lentiviral vectors that are being used for more and more clinical trials and more prevalent diseases.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

The Pharma Data

AUGUST 17, 2021

An experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.

Medicine 52

Medicine Dermatology Production Development 52

The Pharma Data

NOVEMBER 25, 2020

Shafi Khan , Burkhan World’s VP of Business Development stated, “Burkhan is honoured to have partnered up with Vivera in supporting its efforts globally in the medical supply sector. With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. ,

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Manufacturing Licensing 52

pharmaphorum

NOVEMBER 15, 2022

Joining her onstage were Dominique Bridon CEO of Diaccurate, Matthias Müllenbeck SVP, head global business development & alliance management Merck KGaA, and Catherine Pickering CEO iOnctura. It’s a bit of a balance, noted Pickering. The post LSX Inv€$tival Showcase round-up appeared first on.

Life Science 90

Life Science Pharma Companies Marketing Production 90

The Pharma Data

JANUARY 12, 2021

As part of this role he built innovative, high-performing development teams and managed the Regeneron’s regulatory filings, interactions with regulatory agencies, product launches, and business development and licensing activities across its product portfolio.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Pharmaceutical Technology

FEBRUARY 22, 2023

Spanish pharmaceutical firm Ferrer and Swiss biotechnology firm Asceneuron have signed a licensing agreement for the latter’s O-GlcNAcase inhibitor, ASN90, to treat progressive supranuclear palsy (PSP). The company now intends to conduct a Phase II clinical trial for determining the optimal dose range and efficacy of ASN90.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

The Pharma Data

JULY 29, 2021

Research and development expenses increased 30% to $3.3 billion in the quarter primarily due to higher license and asset acquisition charges and an in-process research and development (IPR&D) impairment charge. On a non-GAAP basis, research and development expenses increased 4% to $2.3 and Non-GAAP EPS of $1.93

Production 52

Production Sales Development Licensing 52

The Pharma Data

OCTOBER 27, 2020

Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES : Doreen McMorran: doreen@ovationscience.com Phone: 604-283-0903 ext. SOURCE: Ovation Science Inc. .

Sales 52

Sales Production Drug Delivery Development 52

The Pharma Data

NOVEMBER 3, 2020

Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). About LogicBio Therapeutics. LogicBio is headquartered in Lexington, Mass.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

DECEMBER 8, 2020

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

NOVEMBER 10, 2020

AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies.

Development 40

Development Drugs Protein Research 40

The Pharma Data

JANUARY 4, 2021

. Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

The Pharma Data

JANUARY 27, 2021

Finalized the technical development of modia , a digital therapy for opioid use disorder, for which Orexo owns the exclusive global rights. Entered an exclusive license and supply agreement with Accord Healthcare for ZUBSOLV® covering 29 European countries. Important events after the period.

Production 52

Production Marketing Sales Licensing 52

The Pharma Data

NOVEMBER 5, 2020

VectivBio AG – Based in Switzerland, VectivBio named Sarah Holland as chief business officer and Aditya Venugopal as head of business development. Most recently, Holland served as Global Head of licensing at Lonza AG. Prior to Lonza, she led External Science and Partnering across the globe for Sanofi R&D.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. Sales at Corn Seed & Traits remained at the level of the prior-year quarter (Fx & portfolio adj. percent.

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. Research and development expenses were $3.4

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

NOVEMBER 5, 2020

The FDA accepted for priority review, with a target action date of February 28, 2021 , the supplemental Biologics License Application (sBLA) for Libtayo ® (cemiplimab) as monotherapy to treat patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with ?50% Corporate and Business Development Update.

Sales 52

Sales Production Manufacturing Antibody 52

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Simone Oostindie, PhD, Director, Research and Discovery, Gyes, on: ‘Avidity engineering: A next frontier in the development of differentiating antibody therapeutics’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. Reached a settlement with Teva Pharmaceutical USA, Inc. FDA approval, and customary exceptions). Strengthened Board of Directors with the appointment of Dr. . ;

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

AUGUST 3, 2021

Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities. Acquired IPR&D expenses in 2021 were driven by the Five Prime Therapeutics acquisition. Tezepelumab.

Sales 52

Sales Production Antibody Development 52

Drug Discovery World

SEPTEMBER 6, 2022

Fully booked service providers for manufacturing and sample analyses and more immune-oriented use of gene and cell therapies.” – CBO Aino Kalervo, and VP of Business Development? .” – Andrew Scharenberg, Umoja Biopharma CEO. . Víctor Cervera-Carrascón, Tilt Bio. . Workforce .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52